目的 探討桑枝顆粒聯(lián)合達格列凈片治療2型糖尿病的臨床療效。方法 選取2017年4月—2018年4月在駐馬店市中心醫(yī)院治療的2型糖尿病患者94例，根據(jù)用藥的差別分為對照組（47例）和治療組（47例）。對照組口服達格列凈片，起始劑量5 mg/次，1次/d，根據(jù)血糖可調整劑量至10 mg/次，1次/d；治療組在對照組基礎上口服桑枝顆粒，3 g/次，3次/d。兩組均治療4周。觀察兩組患者臨床療效，同時比較治療前后兩組患者血糖相關指標、HOMA-β和HOMA-IR及血清學指標。結果 治療后，對照組和治療組臨床有效率分別為82.98%和97.87%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組空腹血糖（FBG）、餐后2 h血糖（2 h PG）、糖化血紅蛋白（HbA1c）和胰島素（FINS）水平均顯著降低（P<0.05），且治療后治療組這些血糖相關指標明顯低于對照組（P<0.05）。治療后，兩組HOMA-β均顯著增高（P<0.05），HOMA-IR顯著降低（P<0.05），且治療組HOMA-β和HOMA-IR水平明顯好于對照組（P<0.05）。治療后，兩組γ-谷氨酰轉肽酶（γ-GT）、血管細胞黏附分子-1（VCAM-1）、單核細胞趨化蛋白-1（MCP-1）水平均顯著降低（P<0.05），分泌型卷曲相關蛋白-5（SFRP5）水平顯著增加（P<0.05），且治療組這些血清學指標水平明顯優(yōu)于對照組（P<0.05）。結論 桑枝顆粒聯(lián)合達格列凈片治療2型糖尿病可有效控制患者血糖水平，改善胰島素抵抗及提高胰島素敏感性，具有一定的臨床推廣應用價值。

Objective To investigate the clinical efficacy of Sangzhi Granules combined with Dapagliflozin Tablets in treatment of type 2 diabetes mellitus. Methods Patients (94 cases) with type 2 diabetes mellitus in Zhumadian Central Hospital from April 2017 to April 2018 were divided into control (47 cases) and treatment (47 cases) groups according to different treatments. Patients in the control group were po administered with Dapagliflozin Tablets, and the initial dose was 5 mg/time, once daily, then adjusted to 10 mg/time of maximum dose according to blood glucose, once daily. Patients in the treatment group were po administered with Sangzhi Granules on the basis of the control group, 3 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the blood glucose related indicators, HOMA-β, HOMA-IR and the serological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 82.98% and 97.87%, respectively, and there were differences between two groups (P<0.05). After treatment, the FPG, 2 h PG, HbAlc, and FINS levels in two groups were significantly decreased (P<0.05), and these blood glucose related indicators in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the HOMA-β in two groups was significantly increased (P<0.05), but HOMA-IR was significantly decreased (P<0.05), and the HOMA-β and HOMA-IR levels in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the MCP-1, VCAM-1 and γ-GT levels in two groups were significantly decreased (P<0.05), but SFRP5 levels was significantly increased (P<0.05), and these serological indexes in the treatment group were significantly better than those in the control group (P<0.05). Conclusion Sangzhi Granules combined with Dapagliflozin Tablets in treatment of type 2 diabetes mellitus can effectively control the blood glucose level, improve the insulin resistance and the insulin sensitivity, which has a certain clinical application value.